AIM
KYNB

Axiom Investment Management’s Kyntra Bio KYNB Stock Holding History

Axiom Investment Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.32K Hold
704
– – ﹤0.01% 396
2026
Q1 		$4.77K Buy
+704
New +$5.51K ﹤0.01% 347
2022
Q4 		– Sell
-160
Closed -$52K – 211
2022
Q3 		$52K Buy
+160
New +$51.5K 0.1% 151
2021
Q2 		– Sell
-40
Closed -$35K – 176
2021
Q1 		$35K Buy
+40
New +$42.6K 0.03% 165

Other funds holding KYNB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Axiom Investment Management's KYNB Position: Q2 2026 in Review

Axiom Investment Management held its Kyntra Bio (KYNB) position steady in Q2 2026 at 704 shares worth $5.32K. The position accounts for ﹤0.01% of the portfolio, ranked #396.

Axiom Investment Management first reported a position in KYNB in Q1 2021 and has held it in 4 quarters since. The position peaked at $52K in Q3 2022. 21 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • Axiom Investment Management held 704 shares of Kyntra Bio worth $5.32K as of Q2 2026.
  • Axiom Investment Management left its Kyntra Bio share count unchanged in Q2 2026.
  • Kyntra Bio made up ﹤0.01% of Axiom Investment Management's portfolio in Q2 2026, its #396 holding.
  • Axiom Investment Management first reported a position in Kyntra Bio in Q1 2021 and has held it in 4 quarters since.
  • Axiom Investment Management's Kyntra Bio position peaked at $52K in Q3 2022.
  • 21 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.